Samabriva is a biotechnology company which has developed a disruptive platform (the “RHIZOBRIVA™” platform) from plant material enabling the production of biomolecules suitable for the pharmaceutical industry, as well as the cosmetics, agrochemicals and food industries. More recently, Samabriva has built an independent business unit (the“NANOBRIVA™” platform) focused on the development of orphan drugs for the treatment of lysosomal storage disorders (« LSD »). In this business unit, the company develops proprietary lysosomal enzymes with novel and enhanced bioavailability features, taking advantage of an innovative technology compatible with all production systems (mammalian cell cultures, bacteria, etc …).